Hebei Senlang Biotechnology Co. Ltd.

Research into the potential for tumor-infiltrating lymphocytes (TILs) as a personalized cancer therapy was first begun around 30 years ago, but the cell therapy’s time may finally have come. A new aca

Mega funding deals recently returned to Chinese bioventures developing small molecule drugs, as investors seemingly reignited their enthusiasm for such companies. Reistone Biopharma Company Limited ,